VE1 antibody immunoreactivity in normal anterior pituitary and adrenal cortex without detectable BRAF V600E mutations

American Journal of Clinical Pathology

Volumn 141, Issue 6, 2014, Pages 811-815

  Mordes, Daniel A ^a   Lynch, Kerry ^a   Campbell, Sharon ^a   Dias Santagata, Dora ^a   Nose, Vania ^a   Louis, David N ^a   Hoang, Mai P ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adrenal gland; BRAF V600E; Immunohistochemistry; Pituitary gland; VE1

Indexed keywords

ADENOHYPOPHYSIS HORMONE; B RAF KINASE; CORTICOTROPIN; FOLLITROPIN; FOLLITROPIN ALPHA FRAGMENT; GROWTH HORMONE; LUTEINIZING HORMONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY VE1; PROLACTIN; THYROTROPIN; UNCLASSIFIED DRUG;

ACTH SECRETING CELL; ADENOHYPOPHYSIS; ADRENAL CORTEX; ADRENAL GLAND; ADRENAL MEDULLA; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPHYSIS INTERMEDIATE LOBE; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MUTATIONAL ANALYSIS; PANCREAS; PARATHYROID GLAND; PRIORITY JOURNAL; THYROID GLAND; ZONA FASCICULATA;

ADRENAL GLAND; BRAF V600E; IMMUNOHISTOCHEMISTRY; PITUITARY GLAND; VE1;

ADRENAL CORTEX; AMINO ACID SUBSTITUTION; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; DNA MUTATIONAL ANALYSIS; GENOTYPING TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; MUTATION, MISSENSE; PITUITARY GLAND, ANTERIOR; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; TUMOR MARKERS, BIOLOGICAL;

EID: 84904497611     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP37TLZLTUAOJL     Document Type: Article

References (19)

1. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364:2305-2315.
2. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytomas, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121:397-405.
3. Dias-Santagata D, Lam Q, Vernovsky K, et al. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One. 2011;6:e17948.
4. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011;29:1239-1246.
5. Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine. 2012;91:274-286.
6. Tannapfel A, Sommerer F, Benicke M, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 2003;52:706-712. (Pubitemid 36528874)
7. Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65:6063-6069.
8. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29:3574-3579.
9. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122:11-19.
10. Sinicrope FA, Smyrk TC, Tougeron D, et al. Mutation-specific antibody detects mutant BRAF(V600E) protein expression in human colon carcinomas. Cancer. 2013;119:2765-2770.
11. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012;123:223-233.
12. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol. 2013;37:61-65.
13. Routhier CA, Mochel MC, Lynch K, et al. Comparison of two monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum Pathol. 2013;44:2563-2570.
14. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumors: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010;2:146-158.
15. Sperveslage J, Gierke M, Capper D, et al. VE1 immunohistochemistry in pituitary adenomas is not associated with BRAFV600E mutation. Acta Neuropathol. 2013;125:911-912.
16. De Martino I, Fedele M, Palmieri D, et al. B-RAF mutations are a rare event in pituitary adenomas. J Endocrinol Invest. 2007;30:RC1-RC3. (Pubitemid 46470374)
17. Ida CM, Vrana J A, Rodriguez FJ, et al. Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma. Acta Neuropathol Commun. 2013;1:20.
18. Mesteri I, Bayer G, Meyer J, et al. Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E. Mod Pathol. 2013;27:135-144.
19. Bösmüller H, Fischer A, Pham DL, et al. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol. 2013;44:329-335.